Another study was conducted in order to determine the relationship of HER2 status with time to recurrence (TTR) in postmenopausal women with HR+ primary breast cancer in the large, randomised the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant trial. Here, ERBB2 is linked to breast cancer.